pneumococcal vaccine

pivot change turnaround direction walk away
Biotech

GSK axes vaccine from $2.1B deal, switches to preclinical heir

GSK has axed a pneumococcal 24-valent vaccine for adults from its $2.1 billion Affinivax takeover in favor of a preclinical 30-plus valent shot.
Nick Paul Taylor Oct 30, 2024 7:06am
vaccine diversity flu covid shot needle

Vaxcyte surges on 'stunning' 31-valent PCV win against Pfizer

Sep 3, 2024 10:32am
Photo of a syringe and two vials labeled pneumococcal vaccine

Merck compares pneumococcal vaccine to 1983 warhorse

Apr 29, 2024 9:00am
predictive analytics

GSK tips 12 blockbuster launches to soften HIV patent loss

Jan 31, 2024 7:45am
showdown clash versus vs crash lightning fight dispute

Merck strides onto Pfizer’s turf with pivotal vaccine data

Nov 28, 2023 8:20am
Pfizer

Pfizer axes RSV, eczema, sickle cell and cancer drugs in cull

Aug 1, 2023 9:00am